Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: A randomized, double-blind study

Acta Neurologica Scandinavica

Volumn 106, Issue 2, 2002, Pages 84-92

  Hillbom, M ^a   Erila T ^b   Sotaniemi, K ^a   Tatlisumak, T ^c   Sarna, S ^d   Kaste, M ^c  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Enoxaparin; Ischaemic stroke; Low molecular weight heparin; Thromboprophylaxis

Indexed keywords

ENOXAPARIN; HEPARIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PROPHYLAXIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTICOAGULANTS; ASPARTATE AMINOTRANSFERASES; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; HEMOGLOBINS; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0036321797     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2002.01215.x     Document Type: Article

References (43)

1. Complications after acute stroke
2. Prophylaxis of venous thromboembolism in stroke patients
3. The prevalence of risk factors for venous thromboembolism among hospital patients
4. The venous thrombotic risk in nonsurgical patients
5. Deep vein thrombosis of the legs after strokes
6. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
7. Autopsy-verified causes of death after stroke
8. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. A randomized controlled trial
9. Prophylaxe venöser thrombosen bei frischem ischämischem zerebrovaskulärem insult
10. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke
11. Double-blind randomised trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke
12. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients
13. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III
14. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs)
15. Low-molecular-weight heparin for the treatment of acute ischemic stroke
16. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke
17. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement
18. Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplasty
19. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
20. Roentgen diagnosis of venous thrombosis in the leg
21. Sample size requirements for evaluating a conservative therapy
22. Klinik der akuten bein- und beckenvenenthrombose
23. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study
24. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke
25. Tissue plasminogen activator for acute ischemic stroke
26. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
27. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
28. Streptokinase for acute ischemic stroke with relationship to time of administration
29. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
30. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
31. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
32. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture
33. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
34. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo
35. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin
36. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty
37. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin
38. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
39. Low molecular weight heparin in prevention of perioperative thrombosis
40. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials
41. Low-molecular-weight heparins
42. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
43. Cost-effectiveness of venous thrombosis prophylaxis following ischaemic stroke: An assessment of currently available literature